This document discusses wide complex tachycardia (WCT), which is defined as a heart rate over 100 beats per minute with a QRS duration greater than 120 ms. The main causes of WCT are ventricular tachycardia (VT), supraventricular tachycardia (SVT) with abnormal conduction, and ventricular pacing rhythms. The document outlines various diagnostic features on ECG that can help differentiate VT from SVT such as QRS axis, morphology, presence of AV dissociation, and criteria involving leads aVR and lead II R-wave peak time. Algorithms combining multiple ECG criteria can identify VT with high sensitivity and specificity. History, physical exam findings, and response to treatments may also provide
Ventricular tachycardia are difficult to understand. it is classified in to two types. 1. VT in structurally normal heart, 2. VT in heart with structural diseases. I have tried to simplify the VT in structurally normal heart, which may be helpful to many students and learners.
Ventricular tachycardia are difficult to understand. it is classified in to two types. 1. VT in structurally normal heart, 2. VT in heart with structural diseases. I have tried to simplify the VT in structurally normal heart, which may be helpful to many students and learners.
differentiating between supraventicular tachycardia and ventricular tachycardia in wide complex rhythm is always confusing and management is totally different. correct diagnosis will make dramatic difference in patient management.
Its a medical presentation describing how to approach to various cardiac arrhythmias in systematic way. Illustrated with more ECG photographs from standard sources.
differentiating between supraventicular tachycardia and ventricular tachycardia in wide complex rhythm is always confusing and management is totally different. correct diagnosis will make dramatic difference in patient management.
Its a medical presentation describing how to approach to various cardiac arrhythmias in systematic way. Illustrated with more ECG photographs from standard sources.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
3. Wide complex tachycardia
• Wide Complex Tachycardias (WCT) – QRS duration > 120 ms and heart
rate > 100 beats/min
• Less synchronous ventricular activation of longer duration which can
be due to intraventricular conduction disturbances ,ventricular
activation not mediated by his bundle but by bypass tract or site with
in ventricle
• Correct diagnosis is important for the acute as well as long term
management of patients
• Categories of WCTs include ventricular tachycardia (VT), SVT with
abnormal intraventricular conduction, and ventricular paced rhythms
4. Intra ventricular conduction delay
• Structural abnormality of his purkinje system
• Structural abnormality of ventricular myocardium
• Functional refractoriness in a portion of conduction system
5. Differential diagnosis
VT – 80% of Wide QRS Complex Tachycardia
SVT with abberancy 15 to 20%---functional BBB , pre existing BBB
Pre excited SVT– antidromic AVRT,AT or AVNRT with bystander bypass
tract – 1% to 6%
SVT with pre existing non aberration QRS abnormality
SVT with anti arrhythmic drugs---class IA,IC
Electrolyte imbalances-----Hyperkalemia
Ventricular pacing
6. age
• Age more than 35 years VT (PPV 85%)
• Age less than 35 years SVT(PPV 70%)
7. symptoms
• Mis diagnosis on the basis of symptoms and haemodynamic stability
is a common error that can lead to inappropriate and potentially
dangerous therapy.
• Duration recurrence over a period of more than 3 years SVT more
likely.
8. Underlying heart disease
• Post MI --98% VT
• 7% SVT
• VT can occur in those which structurally normal heart disease,
• SVT can occur in those with structural heart disease.
9. History
• History of pacemaker
• History of drugs --quinidine,sotalol,dofetilide,erythromycin,diuretics
leading hypokalemia and hypomagnesemia
• Digoxin---monomorphic VT,Biderectional VT,Non paroxysmal
Junctional tachycardia
10. examination
• Prominent a WAVE IN JVP SVT
• INTERMITTENT cannon A waves VT
• CAROTID SINUS MASSAGE—
AVRT/AVNRT CAN BE TERMINATED
VT cannot be terminated ,but atrial rate may be slowed
down, expose the av dissociation
11. ECG
• Rate: limited use in distinguishing VT from SVT as there is too much overlap
• Consider Atrial flutter when HR is ~150 beats/min
• Regularity: VT is generally regular, though there can be slight variation in
the RR intervals
• Slight irregularity at the onset (“warm-up phenomenon”) favours VT
• Grossly irregular WCT likely represents:
1) AF w/ aberrant conduction,,
2) AF w/ conduction over an accessory pathway,,
3) polymorphic VT
• Uniformity of the RR intervals favours SVT
12.
13.
14. ●
●
A
Vdissociation :
The most specific ECG finding for VT .
Cluesfor A
Vdissociation:
1. ClinicallybycannonAwaves, variableintensity ofS1, Variation
in SBPunrelated to respiration.
2. A
Vdissociation
3. A
Vratio of lessthan 1
4. 2:1 V
Ablock(d/t retrograde conduction)
5. V
ariation in QRSamplitude duringWCT
6. Fusion &capture beats,dissociatedpwaves
Wide complex tachycardia
15. ECG-AV DISSOCIATION
• Complete AVD occurs in 20-50% of all VTs
• 15-20% VTs have second degree AV block
• 30% of VTs have 1:1 retrograde conduction
• QRS complex amplitude variation,T wave changes
• Transient retrograde blocks can be induced by carotid sinus massage
• Prevalence varies due to
1. Tachycardia rate
2. Amount of ECG recording available
3. Observer experience
4. Observer confidence
• Use lewis leads, echocardiography, oesophageal electrode, transvenous electrode
16. Av dissociation
• Sub atrial SVT JUNCTIONAL ECTOPIC TACHYCARDIA
NODO FASCICULAR REENTRANT TACHYCARDIA
17. DISSOCIATE P WAVES
• P WAVE NOT VISIBLE----
• LEWIS LEAD
• OESOPHAGEAL LEAD,
• RA RECORDING,
• CAROTID SINUS MASSAGE,
• EP TESTING
18. ● Featuresfor differentiation :
● Historyand physical examination:
1. H/o heart disease– previousMI, angina, CHF– have a PPA of
95%for diagnosingVT
2. Pts with VT are older than SVT (> 35 yrs)
3. SVT-Aoften have h/o previous episode(>3years)
4. Pts with SVT-Aare hemodynamicallystable.
5. Examination for A
Vdissociation
a. CannonAwaves in JVP
b. V
ariable S1intensity
c. Variation in SBPunrelated to respiration.
6. Termination ofWCT with physical manoeuvres(catotidsinus
massage) and medications (adenosisne)
Wide complex tachycardia
21. ●
●
●
1. QRSduration :
> 160 ms with LBBB , >140 ms with RBBB - VT
Wellenset al . Showed that 69%of VT had QRSduration of
>140ms and none of SVT-Ashowed QRS duration of >140ms.
Exceptions:
a. Anti arrythmitic drugs non specifically prolong QRS duration.
b. Pts with structurallynormal heart mayhaveVT with QRS
duration of 120-140ms.(<140ms in12% , < 120 ms in 4%)
c. QRS duration also depend site of origin of VT, septal VTOR
FASICULARVT
Wide complex tachycardia
QRS duration hassensitivity of 70%
23. ●
●
●
●
2. QRSaxis:
Frontal plane axis of -90 to +180 --- VT
Shift in QRS axis of more than 40 from baseline --- VT(less
specific)
RBBBwith LAD, LBBBwith RAD --- VT.
RBBBwithnormalaxissuggestSVT.
Wide complex tachycardia
24. ●
●
3. Concordant QRSin chest leads:
Concordant QRSin chest leadsis diagnosticof VT uncommon in
SVT-A.(negativemoresuggestivethanpositive)
Exceptions:
●
● Positive concordance (ventricular activation begins left
posteriorly) seen in VToriginating in Lt post wall or SVTusing a
left posterior accessorypathway forA
Vconduction.
Ifno additional criteria for WPW are absent don’t consider it
because oflow incidence(<6%)
Wide complex tachycardia
Specificity of 90%, Sensitivity of 20%
26. ●
●
●
3. Concordant QRSin limb leads:
The presence of predominantly negative QRS complexes in leads
1,2,3 is suggestive ofVT
This isanother wayto describe right superior axis
Similar to RSaxis it is considered ashighlyspecific for VT
Wide complex tachycardia
27. 4. Pericardial RSduration criteria:
● Ifconcordant QRScomplexes are absent i.e with RScomplex
onset of R wave to nadir of Swave > 100 ms.
Wide complex tachycardia
Sensitivity – 66%
Specificity - 98%
28. ●
●
●
5. RBBB– V1 :
rSr , rSR , rR , rsr patterns consistent with SVT-A
R , R>30ms with any negative QRS, qR --- VT
Thisis because right ventricle doesn’t participate in initial QRS
Wide complex tachycardia
Sensitivity – 30-80%
Specificity - 84-95%
32. ●
●
●
5. Ambiguous chest lead pattern:
W and Mpattern in V1 have been classified asLBBB&RBBB
Because theyare ambiguousin this way, theyare unlikelyto
represent typical aberration and are highlyspecificfor VT.
Sensitivityof 60-80%, specificity of90-95%.
Wide complex tachycardia
35. ●
●
●
6. Q wave presence :
Q duringWCT --- suggest old MI--- VTmost likely.
Ingeneralpts with post MIVTmaintainQ waveduringWCT that
are present during baseline in the same lead.
Exceptions:
1. Pts with DCMPwill have Q wave duringVT that are not present
during baseline.
2. PSEUDO Q wave with retrograde p wave deforming QRScan
be seen in SVT-A
3. Preexcited tachycardia with posteriorA
Vconnection can haveQ
wave in inferior leads
Wide complex tachycardia
38. Wide complex tachycardia
Lead IIR-wave-peak-time (RWPT) criterion : Pavas criteria
RWPT > or =50 ms at DII is a
simple and highlysensitive
criterion that discriminates VT
from SVT in patients with wide
QRScomplex tachycardia.
Heart Rhythm. 2010 Jul;7(7):922-6. Epub2010 Mar4.
Sensitivityand
specificity of 97%
39. Morphologic criteria
Initial R
more than
40ms
In the presence of LBBB like morphology
Capture beats
Fusion beats
Notch Any Q in V6
Rapid
downstroke
No q
LBBB
aberration
47. 7. A
Vdissociation :
Wide complex tachycardia
VT with retrograde 2:1 V
Aconduction (seen in 15-20%ofVT)
48. ● V
ariation in amplitude of QRSduringWCT
1. Scalar summation ofPwave with QRS
2. V
ariable ventricular filling in the presence ofA
VD
● Presence of multiple WCT configuration hasasensitivity of 55%
for diagnosingVT
7. A
Vdissociation :
Wide complex tachycardia
53. ● The QRS complex is prolonged, and the R-R interval is regular
except for occasional capture beats (C) that have anormal contour
and are slightly premature. Complexes intermediate in contour
represent fusion beats (F).
● Thus, even though atrial activity is not clearly apparent,
atrioventricular dissociation is present during ventricular
tachycardia and produces intermittent capture and fusion beats
7. A
Vdissociation :
Wide complex tachycardia
57. 7. A
Vdissociation :
● Caveatswhile usingA
VD:
1. Low sensitivity(20-50%) is d/t fast heart rates, inadequate
duration of recording , observer inexperience.
2. 30%ofpts , especiallyVTwith lowVrate , have1:1 V
A
conduction – differentiate by vagalmaneuvers , adnosine.
3. AFand VT co existA
VD cannot be diagnosed .
Wide complex tachycardia
Sensitivity– 20-50%
Specificity – 98%
58. 8. Base line QRSprolongation:
a. Pt with baseline QRSrhythm and WCT QRSdifferent – VT
1. QRSduringVT is narrower than baseline rhythm
2. Contralateral BBBin baseline rhythm and duringWCT
3. A
Vdissociation
4. Rarely other findings maybe useful like precordial concordance ,
north-west axis , monophasic R wave in V1
Wide complex tachycardia
Ptswith BBRT Impulse originatesin RBB TravelsthroughLBB
Have typical featuresofLBBB
59. 9. aVRchanges:
1. Presence of initial ‘r’wave in aVR
2. Presence of initial ‘r’or ‘q’wave of > 40ms duration
3. Presence of notchin descending limb of negative onset and
predominantlynegative QRS
4. Vi/Vt ≤ 1
All the above features are indicative ofVT
Wide complex tachycardia
Sensitivity– 96.7%
Specificity – 99%
60. 9.
Wide complex tachycardia
aVRchanges: Initial ‘r’
wave in aVR
DuringSVT with aberrancy,
initial septal activation and main
ventricular activation are
directed awayfrom lead aVR
negative QRScomplex
Exceptions:
1. Inferior MI- initial r wave (rScomplex) duringNSRor SVT
2. VToriginating from base of heart may not have initial r wave
62. Wide complex tachycardia
9. aVRchanges: Vi/ Vt ≤ 1
● Vi = voltage in the initial 40ms of QRS
● Vt = voltage in the terminal 40msof QRS
● In SVT-Aonly one portion is bundle branch is blocked --- so the
initial portion of QRSis rapid compared to terminal portion.
● InVTslow muscle to muscle spread of impulse causes slower
voltage changesthroughout QRScomplex
● Can be applied to anylead
● The vi/vt was> 1 (signifyingsupraventricular origin) in 88%
tracingswith LBBBpattern, in 98% with RBBBpattern, and
90% with nonspecific IVCD.
64. Wide complex tachycardia
Lead IIR-wave-peak-time (RWPT) criterion : Pavas criteria
RWPT > or =50 ms at DII is a
simple and highlysensitive
criterion that discriminates VT
from SVT in patients with wide
QRScomplex tachycardia.
Heart Rhythm. 2010 Jul;7(7):922-6. Epub2010 Mar4.
Sensitivityand
specificity of 97%
68. PRECORDIAL RS ABSENT
• Absence of RS in any precordial lead in any lead suggests VT
• In a analysis of 554 WCTs (384 VTs and 170 SVTs) RS was absent in 83
(15%) all were VTs
72. Why RS interval 100 ms indicates VT ?
Normally ventricular activation speed up by the
virtue of Purkinje fibers
<100 ms
73. Why RS interval 100 ms indicates VT ?
Subepicardial origin of VT delay
ventricular activation
>100 ms
Again.. RS <100 ms does not preclude VT
74. Morphologic criteria
Initial R
more than
40ms
In the presence of LBBB like morphology
Capture beats
Fusion beats
Notch Any Q in V6
Rapid
downstroke
No q
LBBB
aberration
76. WCT
Wide complex tachycardia
Diagnostic approach/algorithms
NO YES
INDEPENDENTPWA
VES
YES
VT
Griffith MJ,GarrattCi,etVTasdefault diagnosisin
broadcomplextachycardia.Lancet1994 feb
Sensitivity – 95%
Specificity– 64%
GRIFFITH CRITERIA
77. Wide complex tachycardia
Diagnostic approach/algorithms BAYESIAN CRITERIA
CRITERIA LR
QRS WIDTH
=140MS 0.31
140-160MS 0.48
> 160MS 22.86
QRS AXIS
NWAXIS 7.86
RBBB + LAD 8.21
LBBB + RAD 3.93
NONE 0.47
V WAVE IN RBBB
TALLER LT
PEAK
50
Rs OR qR 4.03
rsR OR rR 0.21
NONE 1.41
V WAVE IN LBBB
r > 40MS 50
NOTCH IN ‘S’ 50
R-S > 60MS 50
NONE 0.13
INTRINSICOID IN V6
= 60MS 19.3
< 60MS 0.46
V6 MORPHOLOGY
QS 50
BIPHASIC RBBB R/S<1 50
TRIPHASIC RBBB
R/S<1
0.13
Sensitivity – 95%
Specificity – 52%
78. Wide complex tachycardia
Diagnostic approach/algorithms aVR CRITERIA
Heart Rhythm, , V
ereckei, A. et al. New
algorithmusingonlyleadaVRforDDof wide
QRScomplextachycardia., 2008
Sensitivity– 96.7%
Specificity – 99%
79. Wide complex tachycardia
Diagnostic approach/algorithms
Sen.10%
Spe.100%
Sen.48%
Spe.98%
Sen.89%
Spe.89%
Sen.95%
Spe.80%
The sensitivity [95.7 vs.
88.2, P< 0.001]and NPV
[83.5%vs. 65.3% for VT
diagnosis ofthe new
algorithmwere superior to
those of the Brugada criteria
Application of anewalgorithmin the DD
of wideQRScomplextachycardia Andra´s
V
ereckei et al . EHJ2007.
80. Wide complex tachycardia
ALGORITHM ORIGINAL STUDY LAU & NG(2001)
ISENHOUR(2000) SEN. SPEF. SEN.
SPE. SEN SPE.
BRUGADA 98.7 96.5 92 44 79-91 43-70
GRIFFITH 95 64 92 44
BA
YESIAN 95 52 97 56
Diagnostic approach/algorithms
81. aVR algorithm
1) Evaluate for the presence of an initial R wave
2) Evaluate for the presence of an initial r or q wave with width > 40
msec
3)Evaluate for notching on the descending limb of a negative onset,
predominately negative QRS complex
82. Wide complex tachycardia
Diagnostic approach/algorithms
● Comparison of five electrocardiographic methods for differentiation
of wide QRS-complex tachycardias
● Brugada,Bayesian,Griffith, andaVRalgorithms, andthe leadIIR-
wave-peak-time (RWPT) criterion
● All five algorithms/criteria had equal moderate diagnostic accuracy.
● The newer methods were not more accurate than the classic Brugada
algorithm
Comparison of five electrocardiographic methods for differentiation
of wide QRS-complex tachycardias.Jastrzebski.M Europace 2010 feb
14
83. ● Best algorithmic approach for diagnosingWCT
1. BRUGADA
2. aVRcriteria
3. V
ereckei combined criteria(old &aVRcriteria)
Wide complex tachycardia
84. Causes:
Regular :
1. V
entricular tachycardia(80%of WCT)
2. Any SVT with aberrancy(2n
dMCWCT)
3. Any SVT with BBB
4. AnySVTwith delayed conduction d/t drugs and electrolytes
a. ClassIA,IC ; hyperkalemia.
5. AntidromicA
VRT(1-5%) Irregular :
6.Pacemaker mediated rhythm
7. AFwith conduction on preexcitation pathway.
8. Any irregular SVT with aberrancy, BBB.
9. VTin the 1st30 sec , pts on anti arrythmitic drugs – cycle length
varibility.
Wide complex tachycardia
85. Causes of wide QRS TACHYCARDIA
VT MACROREENTRANT VT
FOCAL VT
SVT WITH
ABERRANCY
FUNCTIONAL BBB
PREEXISTENT BBB
PREEXCITED SVT ANTIDROMIC AVRT
AT OR AVNRT WITH BYSTANDER
BYPASS TRACT
ANTIARRYTHMIC DRUGS CLASS 1A,CLASS 1C
AMIODARONE
ELECTROLYTE
ABNORMALITIES
HYPERKALEMIA
86. ●
●
7. A
Vdissociation :
The most specific ECG finding for VT .
Cluesfor A
Vdissociation:
1. ClinicallybycannonAwaves, variableintensity ofS1, Variation
in SBPunrelated to respiration.
2. A
Vdissociation
3. A
Vratio of lessthan 1
4. 2:1 V
Ablock(d/t retrograde conduction)
5. V
ariation in QRSamplitude duringWCT
6. Fusion &capture beats,dissociatedpwaves
Wide complex tachycardia
87. ECG-AV DISSOCIATION
• Complete AVD occurs in 20-50% of all VTs
• 15-20% VTs have second degree AV block
• 30% of VTs have 1:1 retrograde conduction
• QRS complex amplitude variation,T wave changes
• Transient retrograde blocks can be induced by carotid sinus massage
• Prevalence varies due to
1. Tachycardia rate
2. Amount of ECG recording available
3. Observer experience
4. Observer confidence
• Use lewis leads, echocardiography, oesophageal electrode, transvenous electrode
88. Av dissociation
• Sub atrial SVT JUNCTIONAL ECTOPIC TACHYCARDIA
NODO FASCICULAR REENTRANT TACHYCARDIA